- ￥6500
- 齐源
- 305051
- 国产/进口
- 2025年07月14日
- PG
- 小鼠
- 人、猴
6 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
齐源
- 库存：
999
- 靶点：
CD64
- 级别：
CD64 Antibody
- 目录编号：
CD64 Antibody
- 克隆性：
单克隆
- 抗原来源：
小鼠
- 保质期：
CD64 Antibody
- 抗体英文名：
TotalSeq™-D0162 anti-human CD64 Antibody
- 抗体名：
CD64 Antibody
- 标记物：
CD64 Antibody
- 宿主：
小鼠
- 适应物种：
人、猴
- 免疫原：
CD64 Antibody
- 亚型：
CD64 Antibody
- 形态：
CD64 Antibody
- 应用范围：
PG
- 保存条件：
2-8℃
- 浓度：
0.5 mg/mL
- 规格：
10 ug
TotalSeq™-D0162 抗人 CD64 抗体详细如下：
Description ：CD64 is a 72 kD single chain type I glycoprotein also known as FcγRI and FcR I. CD64 is amember of the immunoglobulin superfamily and is expressed on monocytes/macrophages,dendritic cells, and activated granulocytes. The expression can be upregulated by IFN-γstimulation. CD64 binds IgG immune complex. It plays a role in antigen capture, phagocytosisof IgG/antigen complexes, and antibody-dependent cellular cytotoxicity (ADCC).
Verified Reactivity ：Human, Cynomolgus, Rhesus
Reported Reactivity ：Baboon, Capuchin Monkey, Chimpanzee, Squirrel Monkey
Antibody Type ：Monoclonal
Host Species ：Mouse
Immunogen ：Human rheumatoid synovial fluid cells and fibronectin-purified monocytes.
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 1 mM EDTA
Preparation ：The antibody was purified by chromatography and conjugated with TotalSeq™-D oligomer underoptimal conditions.
Concentration ：0.5 mg/mL
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
Application ：PG - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis and the oligomer sequence is confirmed by sequencing. TotalSeq™-D antibodies arecompatible with Mission Bio’s Tapestri Single-Cell Sequencing Platform for simultaneous detectionof DNA and Protein.
To maximize performance, it is strongly recommended that the reagent be titrated for eachapplication, and that you centrifuge the antibody dilution before adding to the cells at 14,000xg at 2- 8°C for 10 minutes. Carefully pipette out the liquid avoiding the bottom of the tube and add to thecell suspension. For Proteogenomics analysis, the suggested starting amount of this reagent fortitration is ≤ 1.0 µg per million cells in 100 µL volume. Refer to the corresponding TotalSeq™protocol for specific staining instructions.
Buyer is solely responsible for determining whether Buyer has all intellectual property rights thatare necessary for Buyer's intended uses of the BioLegend TotalSeq™ products. For example, forany technology platform Buyer uses with TotalSeq™, it is Buyer's sole responsibility to determinewhether it has all necessary third party intellectual property rights to use that platform andTotalSeq™ with that platform.
Application Notes ：Clone 10.1 recognizes the EC3 epitope of CD64. While both contain the EC3 domain, in-housetesting suggests that clone 10.1 preferentially binds to CD64A (FcγRIA), but not CD64B (FcγRIB).Additional reported applications (for the relevant formats) include: blocking of human IgG3 andmurine IgG2a binding to FcγRI and immunohistochemical staining of a-cetone-fixed frozentissue sections .2,5,6,1112
Description ：CD64 is a 72 kD single chain type I glycoprotein also known as FcγRI and FcR I. CD64 is amember of the immunoglobulin superfamily and is expressed on monocytes/macrophages,dendritic cells, and activated granulocytes. The expression can be upregulated by IFN-γstimulation. CD64 binds IgG immune complex. It plays a role in antigen capture, phagocytosisof IgG/antigen complexes, and antibody-dependent cellular cytotoxicity (ADCC).
Verified Reactivity ：Human, Cynomolgus, Rhesus
Reported Reactivity ：Baboon, Capuchin Monkey, Chimpanzee, Squirrel Monkey
Antibody Type ：Monoclonal
Host Species ：Mouse
Immunogen ：Human rheumatoid synovial fluid cells and fibronectin-purified monocytes.
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 1 mM EDTA
Preparation ：The antibody was purified by chromatography and conjugated with TotalSeq™-D oligomer underoptimal conditions.
Concentration ：0.5 mg/mL
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
Application ：PG - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis and the oligomer sequence is confirmed by sequencing. TotalSeq™-D antibodies arecompatible with Mission Bio’s Tapestri Single-Cell Sequencing Platform for simultaneous detectionof DNA and Protein.
To maximize performance, it is strongly recommended that the reagent be titrated for eachapplication, and that you centrifuge the antibody dilution before adding to the cells at 14,000xg at 2- 8°C for 10 minutes. Carefully pipette out the liquid avoiding the bottom of the tube and add to thecell suspension. For Proteogenomics analysis, the suggested starting amount of this reagent fortitration is ≤ 1.0 µg per million cells in 100 µL volume. Refer to the corresponding TotalSeq™protocol for specific staining instructions.
Buyer is solely responsible for determining whether Buyer has all intellectual property rights thatare necessary for Buyer's intended uses of the BioLegend TotalSeq™ products. For example, forany technology platform Buyer uses with TotalSeq™, it is Buyer's sole responsibility to determinewhether it has all necessary third party intellectual property rights to use that platform andTotalSeq™ with that platform.
Application Notes ：Clone 10.1 recognizes the EC3 epitope of CD64. While both contain the EC3 domain, in-housetesting suggests that clone 10.1 preferentially binds to CD64A (FcγRIA), but not CD64B (FcγRIB).Additional reported applications (for the relevant formats) include: blocking of human IgG3 andmurine IgG2a binding to FcγRI and immunohistochemical staining of a-cetone-fixed frozentissue sections .2,5,6,1112
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Application References(PubMed link indicatesBioLegend citation)：
1. McMichael A, et al. Eds. 1987. Leucocyte Typing III. Oxford University Press. New York.
2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. p. 874.
3. Kishimoto T, et al. Eds. 1997. Leucocyte Typing VI. Garland Publishing Inc. London.
4. Holl V, et al. 2004. J. Immunol. 173:6274.
5. Hober D, et al. 2002. J. Gen. Virol. 83:2169.
6. Cho HJ, et al. 2007. Physiol Genomics 149:60.
7. van Tits L, et al. 2005. Arterioscler Thromb Vasc Biol. 25:717. PubMed
8. Bruhns P, et al. 2008. Blood 113:3716. PubMed
9. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
10. Carter DL, et al. 1999. Cytometry 37:41. (FC)
11. Dougherty GJ, et al. 1987. Eur. J. Immunol. 17:1453.
12. Blom AB, et al. 2003. Arthritis Rheum. 48(4):1002-14. (IHC)
1. McMichael A, et al. Eds. 1987. Leucocyte Typing III. Oxford University Press. New York.
2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. p. 874.
3. Kishimoto T, et al. Eds. 1997. Leucocyte Typing VI. Garland Publishing Inc. London.
4. Holl V, et al. 2004. J. Immunol. 173:6274.
5. Hober D, et al. 2002. J. Gen. Virol. 83:2169.
6. Cho HJ, et al. 2007. Physiol Genomics 149:60.
7. van Tits L, et al. 2005. Arterioscler Thromb Vasc Biol. 25:717. PubMed
8. Bruhns P, et al. 2008. Blood 113:3716. PubMed
9. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
10. Carter DL, et al. 1999. Cytometry 37:41. (FC)
11. Dougherty GJ, et al. 1987. Eur. J. Immunol. 17:1453.
12. Blom AB, et al. 2003. Arthritis Rheum. 48(4):1002-14. (IHC)
文献支持
D0162 抗人 CD64 抗体
￥6500
